Literature DB >> 10485660

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity.

S S Cha1, M S Kim, Y H Choi, B J Sung, N K Shin, H C Shin, Y C Sung, B H Oh.   

Abstract

TRAIL is a newly identified cytokine belonging to the large tumor necrosis factor (TNF) family. TRAIL is a novel molecule inducing apoptosis in a wide variety of tumor cells but not in normal cells. To help in elucidating its biological roles and designing mutants with improved therapeutic potential, we have determined the crystal structure of human TRAIL. The structure reveals that a unique frame insertion of 12-16 amino acids adopts a salient loop structure penetrating into the receptor-binding site. The loop drastically alters the common receptor-binding surface of the TNF family most likely for the specific recognition of cognate partners. A structure-based mutagenesis study demonstrates a critical role of the insertion loop in the cytotoxic activity of TRAIL.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485660     DOI: 10.1016/s1074-7613(00)80100-4

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  37 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  A simplified method for the efficient purification and refolding of recombinant human TRAIL.

Authors:  Zhenjiang Zhang; Su Bin Hahn; Thong M Cao; Michael R King
Journal:  Biotechnol Prog       Date:  2020-05-11

3.  Crystallization and preliminary X-ray crystallographic study of the extracellular domain of the 4-1BB ligand, a member of the TNF family.

Authors:  Jung-Sue Byun; Dong-Uk Kim; Byungchan Ahn; Byoung Se Kwon; Hyun-Soo Cho
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-12-16

Review 4.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05

5.  Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.

Authors:  Jerome T Higgs; John S Jarboe; Joo Hyoung Lee; Diptiman Chanda; Carnellia M Lee; Champion Deivanayagam; Selvarangan Ponnazhagan
Journal:  Mol Cancer Res       Date:  2015-01-30       Impact factor: 5.852

6.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

Review 7.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 8.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

Review 9.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

10.  Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

Authors:  Moonsup Jeong; Yong-Sam Kwon; Soon-Hye Park; Chae-Young Kim; Sin-Soo Jeun; Kang-Won Song; Yong Ko; Paul D Robbins; Timothy R Billiar; Byong-Moon Kim; Dai-Wu Seol
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.